<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521404</url>
  </required_header>
  <id_info>
    <org_study_id>CS1008-A-U201</org_study_id>
    <nct_id>NCT00521404</nct_id>
  </id_info>
  <brief_title>Open-label Study of CS1008 for Subjects With Untreated and Unresectable Pancreatic Cancer</brief_title>
  <official_title>Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to
      subjects with previously untreated and unresectable (unable to be surgically removed) or
      metastatic (spread to other areas beyond the pancreas) pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      - To evaluate the efficacy of CS-1008 administered in combination with gemcitabine to
      chemotherapy naive subjects with unresectable or metastatic pancreatic cancer, based on the
      progression-free survival rate at 16 weeks.

      Secondary Objectives:

        -  To evaluate the efficacy of CS-1008 administered in combination with gemcitabine on
           overall progression-free survival rate, objective response rate, duration of response
           and overall survival.

        -  To determine the pharmacokinetics of C-1008 and gemcitabine

        -  To study potential biomarkers of CS-1008 activity

        -  To evaluate the safety profile of CS-1008 when administered in combination with
           gemcitabine to chemotherapy naive subjects with unresectable or metastatic pancreatic
           cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 16 weeks</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate; overall survival rate; Duration of progression-free survival; overall survival; best overall response using RECIST criteria; Analysis of pharmacokinetics; analysis of safety as measured by NCE CTCAE v3.0</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>CS-1008 + gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-1008 + gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-1008 (humanized anti-DR5 antibody)</intervention_name>
    <description>CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.</description>
    <arm_group_label>CS-1008 + gemcitabine</arm_group_label>
    <other_name>CS1008</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Gemcitabine - 1000mg/meter sq</description>
    <arm_group_label>CS-1008 + gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed resectable or metastatic pancreatic cancer;
             not previously treated with chemotherapy; measurable disease; 18 years of age or older

        Exclusion Criteria:

          -  No anticipated need for major surgery or radiation therapy during the study

          -  Heart Disease exclusions:myocardial infarction or unstable angina within the past 6
             months; severe or unstable angina pectoris within the past 6 months; coronary or
             peripheral artery bypass graft within the past 6 mo., etc.

          -  No clinically significant active infection or history of HIV

          -  No partial or complete bowel obstruction

          -  Cannot have poorly controlled psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mansoor Saleh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgia Cancer Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2007</study_first_submitted>
  <study_first_submitted_qc>August 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <disposition_first_submitted>October 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 1, 2010</disposition_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wojtowicz-Praga, Slawomir</name_title>
    <organization>Daiichi Sankyo</organization>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>chemotherapy naive</keyword>
  <keyword>unresectable or metastatic pancreatic cancer</keyword>
  <keyword>CS1008</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Gemzar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

